Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Retained Earnings (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Retained Earnings for 8 consecutive years, with -$528.2 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 9.48% to -$528.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$528.2 million through Dec 2025, down 9.48% year-over-year, with the annual reading at -$528.2 million for FY2025, 9.48% down from the prior year.
  • Retained Earnings for Q4 2025 was -$528.2 million at Precision Biosciences, up from -$548.3 million in the prior quarter.
  • The five-year high for Retained Earnings was -$283.1 million in Q2 2021, with the low at -$548.3 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$430.6 million, with a median of -$459.0 million recorded in 2023.
  • The sharpest move saw Retained Earnings plummeted 49.46% in 2021, then grew 3.65% in 2024.
  • Over 5 years, Retained Earnings stood at -$316.7 million in 2021, then plummeted by 35.25% to -$428.3 million in 2022, then dropped by 14.32% to -$489.6 million in 2023, then increased by 1.46% to -$482.5 million in 2024, then fell by 9.48% to -$528.2 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$528.2 million, -$548.3 million, and -$526.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.